JP2012067116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012067116A5 JP2012067116A5 JP2011246211A JP2011246211A JP2012067116A5 JP 2012067116 A5 JP2012067116 A5 JP 2012067116A5 JP 2011246211 A JP2011246211 A JP 2011246211A JP 2011246211 A JP2011246211 A JP 2011246211A JP 2012067116 A5 JP2012067116 A5 JP 2012067116A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- initial dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57849904P | 2004-06-10 | 2004-06-10 | |
| US60/578,499 | 2004-06-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527795A Division JP2008502738A (ja) | 2004-06-10 | 2005-06-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012067116A JP2012067116A (ja) | 2012-04-05 |
| JP2012067116A5 true JP2012067116A5 (enExample) | 2013-11-07 |
Family
ID=35510259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527795A Withdrawn JP2008502738A (ja) | 2004-06-10 | 2005-06-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
| JP2011246211A Withdrawn JP2012067116A (ja) | 2004-06-10 | 2011-11-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527795A Withdrawn JP2008502738A (ja) | 2004-06-10 | 2005-06-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US7354580B2 (enExample) |
| EP (2) | EP2583685A1 (enExample) |
| JP (2) | JP2008502738A (enExample) |
| CN (1) | CN101102786A (enExample) |
| AU (1) | AU2005254058A1 (enExample) |
| CA (1) | CA2567686A1 (enExample) |
| IL (1) | IL179515A0 (enExample) |
| MX (1) | MXPA06014421A (enExample) |
| WO (1) | WO2005123104A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1755645A2 (en) * | 2004-06-18 | 2007-02-28 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
| CA3142945A1 (en) * | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| AU2006279658A1 (en) * | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a VEGF antagonist |
| US8093259B2 (en) * | 2006-05-25 | 2012-01-10 | Novartis Ag | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| AU2014201795B2 (en) * | 2006-12-19 | 2016-05-19 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| US20080248033A1 (en) * | 2006-12-19 | 2008-10-09 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| CA2746120A1 (en) * | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| HUE052510T2 (hu) | 2009-05-27 | 2021-05-28 | Ptc Therapeutics Inc | Módszerek a rák és a nem daganatos állapotok kezelésére |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| EP2596364B1 (en) * | 2010-07-19 | 2015-12-16 | F.Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途 |
| CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| MY170528A (en) | 2013-02-18 | 2019-08-09 | Vegenics Pty Ltd | Vegfr-3 ligand binding molecules and uses thereof |
| JP6071099B1 (ja) | 2014-01-25 | 2017-02-01 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管の新生又は成長を抑制する融合タンパク質及びその用途 |
| CN104004058B (zh) * | 2014-06-23 | 2016-06-08 | 栾晓鹏 | 有关白介素-33抑制剂多肽及其应用 |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| RS58957B1 (sr) | 2014-07-18 | 2019-08-30 | Sanofi Sa | Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka |
| EP3212233B1 (en) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| HK1242996A1 (zh) * | 2014-11-14 | 2018-07-06 | 豪夫迈．罗氏有限公司 | 预测对vegf拮抗剂的响应 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| AU2017211247B2 (en) * | 2016-01-25 | 2023-03-09 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
| US10947537B2 (en) * | 2016-02-18 | 2021-03-16 | University Of Massachusetts | Method of treating VEGF/VEGFR resistant prostate cancer by combining the therapy with RAC1 inhibitors |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| SG11201908998XA (en) * | 2017-03-30 | 2019-10-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
| US11458126B2 (en) | 2017-08-01 | 2022-10-04 | Ptc Therapeutics, Inc. | DHODH inhibitor for use in treating hematologic cancers |
| WO2019083172A1 (ko) * | 2017-10-24 | 2019-05-02 | 국립암센터 | 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물 |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2020106050A1 (ko) * | 2018-11-20 | 2020-05-28 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성물 |
| WO2020159203A1 (ko) * | 2019-01-29 | 2020-08-06 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물 |
| WO2020159171A2 (ko) * | 2019-02-01 | 2020-08-06 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| US20220196166A1 (en) * | 2020-12-18 | 2022-06-23 | Nibco Inc. | L-ball union drain valve |
| US11898643B1 (en) | 2022-12-28 | 2024-02-13 | Nibco Inc. | Dual union ball drain valve with T-flow adjustability |
| US12140236B2 (en) | 2023-02-08 | 2024-11-12 | Nibco Inc. | Dual union drain valve with reversible check inserts |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| CN101433715B (zh) * | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| AU2004242586C1 (en) * | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| CA2519875C (en) * | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
-
2005
- 2005-06-10 EP EP12176929.3A patent/EP2583685A1/en not_active Withdrawn
- 2005-06-10 EP EP05750079A patent/EP1753442A2/en not_active Ceased
- 2005-06-10 MX MXPA06014421A patent/MXPA06014421A/es not_active Application Discontinuation
- 2005-06-10 US US11/149,738 patent/US7354580B2/en not_active Expired - Lifetime
- 2005-06-10 WO PCT/US2005/020762 patent/WO2005123104A2/en not_active Ceased
- 2005-06-10 CA CA002567686A patent/CA2567686A1/en not_active Abandoned
- 2005-06-10 CN CNA2005800189582A patent/CN101102786A/zh active Pending
- 2005-06-10 JP JP2007527795A patent/JP2008502738A/ja not_active Withdrawn
- 2005-06-10 AU AU2005254058A patent/AU2005254058A1/en not_active Abandoned
-
2006
- 2006-11-23 IL IL179515A patent/IL179515A0/en unknown
-
2008
- 2008-02-29 US US12/072,966 patent/US7482002B2/en not_active Expired - Lifetime
- 2008-02-29 US US12/074,104 patent/US7479274B2/en not_active Expired - Lifetime
- 2008-02-29 US US12/072,965 patent/US7482001B2/en not_active Expired - Lifetime
- 2008-02-29 US US12/074,096 patent/US7479273B2/en not_active Expired - Lifetime
- 2008-02-29 US US12/074,140 patent/US7479275B2/en not_active Expired - Lifetime
- 2008-02-29 US US12/072,967 patent/US7479272B2/en not_active Expired - Lifetime
-
2011
- 2011-11-10 JP JP2011246211A patent/JP2012067116A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008507536A5 (enExample) | ||
| KR102225371B1 (ko) | 플리나불린 및 탁산의 조합에 의한 암 치료 | |
| US11576895B2 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2007515469A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| CN105451750A (zh) | 治疗人的实体肿瘤的诺氏梭菌 | |
| JP2008540364A5 (enExample) | ||
| TWI486172B (zh) | 鼻咽癌治療的醫藥 | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| CN117442704A (zh) | 一种治疗前列腺癌的药物组合及其应用 | |
| JP2013540725A5 (enExample) | ||
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| CN110494137A (zh) | 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途 | |
| CN109963847A (zh) | 治疗实体瘤的方法 | |
| CN114617969A (zh) | 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用 | |
| Papadopoulos et al. | A phase Ia study in patients with advanced solid tumors for the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway | |
| US11911374B2 (en) | Methods and uses for treating cancer | |
| CN103251586B (zh) | 抗血管发生药物为基础的抗肿瘤组合物 | |
| CN121370853A (zh) | Psammaplysene D及其衍生物在制备抗慢性肝病的药物中的应用 | |
| WO2024222705A1 (zh) | 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途 | |
| US20200000769A1 (en) | Medical Uses Of N-(2-Aminoethyl)-N-(4-Benzyloxy)-3-Methoxybenzyl)Thiophene-2-Formamide Hydrochloride | |
| Scott | Combination Therapies for MDS |